AKEBIA THERAPEUTICS INC's ticker is AKBA and the CUSIP is 00972D105. A total of 105 filers reported holding AKEBIA THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $88,563 | -55.4% | 86,826 | -19.9% | 0.03% | -53.4% |
| Q1 2024 | $198,482 | +84.4% | 108,460 | +24.9% | 0.06% | +70.6% |
| Q4 2023 | $107,664 | +41.3% | 86,826 | +29.9% | 0.03% | +21.4% |
| Q3 2023 | $76,182 | +24.6% | 66,826 | 0.0% | 0.03% | +33.3% |
| Q2 2023 | $61,146 | +63.3% | 66,826 | 0.0% | 0.02% | +61.5% |
| Q1 2023 | $37,449 | -2.9% | 66,826 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $38,559 | -51.8% | 66,826 | -73.5% | 0.01% | -56.7% |
| Q3 2022 | $80,000 | -10.1% | 251,826 | 0.0% | 0.03% | +7.1% |
| Q2 2022 | $89,000 | -93.0% | 251,826 | -85.7% | 0.03% | -92.2% |
| Q1 2022 | $1,265,000 | -64.9% | 1,762,731 | +10.6% | 0.36% | -65.9% |
| Q4 2021 | $3,601,000 | -21.5% | 1,593,531 | 0.0% | 1.06% | -23.5% |
| Q3 2021 | $4,589,000 | -24.0% | 1,593,531 | 0.0% | 1.38% | -20.8% |
| Q2 2021 | $6,039,000 | +15.8% | 1,593,531 | +3.5% | 1.74% | +6.3% |
| Q1 2021 | $5,214,000 | +117.2% | 1,540,254 | +79.7% | 1.64% | +60.3% |
| Q4 2020 | $2,400,000 | – | 857,138 | – | 1.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Novo Holdings A/S | 1,887,535 | $37,128,000 | 4.83% |
| FT Options LLC | 190,400 | $1,451,000 | 2.19% |
| DAFNA Capital Management LLC | 135,738 | $2,670,000 | 1.66% |
| Nantahala Capital Management | 1,367,947 | $26,908,000 | 1.32% |
| Perceptive Advisors | 3,260,000 | $64,124,000 | 1.22% |
| EAM Investors, LLC | 235,470 | $4,632,000 | 0.62% |
| 361 CAPITAL LLC | 139,489 | $2,744,000 | 0.53% |
| Opus Point Partners Management, LLC | 21,009 | $413,000 | 0.37% |
| EAGLE ASSET MANAGEMENT INC | 3,043,867 | $59,629,000 | 0.34% |
| Piermont Capital Management Inc. | 27,770 | $546,000 | 0.18% |